Journal article
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial
Arjun Sahgal, Sten D Myrehaug, Shankar Siva, Giuseppina L Masucci, Pejman J Maralani, Michael Brundage, James Butler, Edward Chow, Michael G Fehlings, Mathew Foote, Zsolt Gabos, Jeffrey Greenspoon, Marc Kerba, Young Lee, Mitchell Liu, Stanley K Liu, Isabelle Thibault, Rebecca K Wong, Maaike Hum, Keyue Ding Show all
LANCET ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2021
Abstract
BACKGROUND: Conventional external beam radiotherapy is the standard palliative treatment for spinal metastases; however, complete response rates for pain are as low as 10-20%. Stereotactic body radiotherapy delivers high-dose, ablative radiotherapy. We aimed to compare complete response rates for pain after stereotactic body radiotherapy or conventional external beam radiotherapy in patients with painful spinal metastasis. METHODS: This open-label, multicentre, randomised, controlled, phase 2/3 trial was done at 13 hospitals in Canada and five hospitals in Australia. Patients were eligible if they were aged 18 years and older, and had painful (defined as ≥2 points with the Brief Pain Invento..
View full abstractGrants
Awarded by Canadian Cancer Society
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This trial was funded in Canada by the Canadian Cancer Society (grant number 704970) , and in Australia and New Zealand by the National Health and Medical Research Council (grant number 1141566) , which allowed participation of the Trans Tasman Radiation Oncology Group (TROG) . TROG acted as the local sponsor of the trial in Australia and New Zealand and was responsible for the conduct of the trial according to the protocol documents and applicable laws, rules, regulations, and guidance. We also thank Yvonne Murray and Dora Nomikos of the CCTG for their administrative support.